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ABSTRACT
As the key molecule of type-I-hypersensitivity, IgE provides specificity for the allergen and links it to the allergic
effector functions. Antibodies are secreted by plasma cells and their precursors, the plasma blasts. The fate of
plasma cells is a subject of controversy, with respect to their lifetime and persistence in the absence of aller-
gen. In general, plasma cells were for a long time considered as short-lived end products of B-cell differentia-
tion, and many of them are short-lived, although already for more than 20 years evidence has been provided
that IgE-secreting plasma cells can persist over months. Today long-lived, “memory” plasma cells are consid-
ered to represent a distinct cellular entity of immunological memory, with considerable therapeutic relevance.
Long-lived plasma cells resist current therapeutic and experimental approaches such as immunosuppression,
e.g. cyclophosphamide, steroids, X-ray irradiation, anti-CD20 antibodies and anti-inflammatory drugs, while the
chronic generation of short-lived plasma cells is sensitive to conventional immunosuppression. The seasonal
variation in pollen-specific IgE can be suppressed by immunotherapy, indicating that component of the IgE re-
sponse, which is stimulated with pollen allergen is susceptible to suppression. Targeting of the remaining long-
lived, allergen-specific plasma cells, providing the stable IgE-titers, represents a therapeutic challenge.
Here we discuss recent evidence suggesting, why current protocols for the treatment of IgE-mediated aller-
gies fail: Memory plasma cells generated by inhalation of the allergen become long-lived and are maintained
preferentially in the bone marrow. They do not proliferate, and are refractory to conventional therapies. Current
concepts target plasma cells for depletion, e.g. the proteasome inhibitor bortezomib, BAFF and APRIL antago-
nists and autologous hematopoietic stem cell transplantation.
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INTRODUCTION
IgE-B CELLS IN ALLERGY
IgE Develops by Class Switch of Antibody
Genes
B lymphocytes develop in the bone marrow. They
leave it as mature B cells, expressing IgM and IgD on
their surfaces. These IgM or IgD B cell receptors rec-
ognize antigen specifically and thereby activate the B
cell. If the mature B cell binds its processed antigen
presented on a T helper (Th) cell it is activated. Co-
activation by cytokine signals and signals from
membrane-proteins is the prerequisite for B cell acti-
vation followed by Ig class switch recombination. Ig
class switching occurs by a directed loop-out-and-
deletion-recombination between two highly repetitive
switch regions (SH), resulting in switch transcripts
that are composed of 5’ and 3’ parts of the donor and
acceptor regions, respectively.1 These hybrid switch
regions can serve as donor regions in further switch
recombinations. Although all murine switch regions
have been shown to be involved in sequential switch
recombination, Jung and coworkers report that for Sε
sequential switching via S’γ1 appears to be dominant
over direct switching.1 The frequent observation of
Sγ1 sequences in the chromosomal and excised circu-
lar products of IgE switch recombinations, and the
fact that in vitro, the appearance of IgE+ cells in LPS
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IL-4 cultures can be largely suppressed by anti-IgG1
antibodies, led to the suggestion that most IgE+ cells
are generated by sequential switching. Interestingly,
functional deletion of γ1 membrane exons by gene
targeting showed that switching to downstream Ig
isotypes was not affected, indicating that direct
switching occurs in vivo.2 Direct switching to IgE was
also suggested by Luger and coworkers, as antigen-
specific sequence motifs found in IgE antibodies dif-
fered from those found in IgG1 antibodies. This ar-
gues against the notion that consecutive switch re-
combination via γ1 is a major operational mechanism
in the generation of IgE-expressing B cells in vivo.3
The isotype to which the B cell is switching to de-
pends on the cytokine present during activation. For
instance, interleukin 4, secreted by Th2 cells induces
the immunoglobulin class switch to IgE. Thereby the
B cell keeps its specificity for the antigen, while the
function of the antibody is altered.
From Membrane-Bound IgE to Secreted IgE
During differentiation of activated B cells to plasma
blasts and plasma cells, not only immunoglobulin
class switch takes place but also a change from mem-
brane expression to the secretion of antibody mole-
cules.4 Antibodies, together with the accessory mole-
cules Igα und Igβ are expressed by B cells as
membrane-bound antigen-receptors controlling acti-
vation of the B cell. The constant regions of the im-
munoglobulin heavy chain are encoded by 5 or 6 ex-
ons, depending on the antibody class. All antibody
classes express the last exons alternatively. One
codes for the transmembrane domain of the mem-
brane bound antibody, expressed on naïve and mem-
ory B cells. The other one codes for the last domain
of the secreted antibody. In B cells transcription ends
after the “membrane-exon”, while in plasma cells it is
terminated after the “ secretion-exon ” . The
“membrane-exon” is spliced out of the transcript in
plasma cells.5 Although IgE―as well as all other anti-
body isotypes can exist in both forms, evidence for
IgE-positive memory B cells is rare.6 At any rate―the
frequencies of IgE-positive memory B cells are a
thousand fold lower than IgG-expressing memory B
cells. Though, IgE-positive plasma cells can differenti-
ate from IgG-positive memory B cells after consecu-
tive immunoglobulin class switch recombination.1,4
MAINTENANCE OF MEMORY LYMPHOCYTES
It is a matter of debate in the field of immunology
whether specialized memory cells do exist at all,
branding the term “immunologic memory” for the
cell by cell amplification of antigen-specific lympho-
cytes.7,8 The discussion is based on the present lack
of markers distinguishing between long-lived effector
cells and professional memory cells.8 One may under-
stand this debate, as it is technically highly sophisti-
cated to differentiate between the maintenance of a
pre-existing pool of memory cells and a slow
proliferation-rate.
It is discussed as to what extent effector cells are
maintained by repeated antigen-contact as in e.g.
chronic immune reactions, as compared to “memory”
in its strict sense, i.e. the “maintenance of information
in the absence of effective antigenic instruction”.9
Chronic immune reactions can be driven (i)
antigen-specifically by e.g. residual antigen or (ii) un-
specifically as shown for cross-reactivities. Here, due
to shared T cell epitopes, B cells specific for e.g.
birch pollen major allergen Bet v 1 can be activated
by Th cells recognizing an epitope on apple allergen
Mal d 1.10
Memory in the absence of effective antigenic in-
struction has been demonstrated for B cells, for
memory T cells and for long-lived plasma cells, which
no longer respond to antigen, and rest in terms of
proliferation.11
BIOLOGY OF SYSTEMICALLY INDUCED
PLASMA CELLS
In systemic immune responses analysed so far,
antigen-specific antibody-secreting cells are gener-
ated in secondary lymphoid organs. Most of these
cells then migrate into the bone marrow as plasmab-
lasts.12-14 Essential for this differentiation is the ex-
pression of the transcription factor Blimp-1, which
downregulates the B cell transcription factor Pax-5
(in: 9).
Plasmablasts are proliferating precursors of plasma
cells and can therefore be depleted from the system
by cytostatic drugs such as e.g. cyclophosphamide.
In the bone marrow, migratory plasmablasts appar-
ently differentiate into resident plasma cells and sur-
vive as such over extended periods of time.3,15-18 Al-
though this differentiation and survival has so far only
been shown for IgG-secreting plasma cells, it is as-
sumed that IgE-secreting plasma cells behave simi-
larly. Still, long-lived plasma cells have stopped prolif-
eration and are refractory to antigen.17 As a result,
conventional immunosuppressive therapy is ineffec-
tive as it is aiming at suppression of the development
of plasma cells. Survival of these long-lived plasma
cells is likely to be due to signals from their environ-
ment,19-21 forming a plasma cell survival “niche”.
Plasma cells relocated from their survival niches will
probably die, because they are no longer migratory
and are deprived of their survival signals.13,19
CLASSICAL PLASMA CELL SURVIVAL NICHES
AND “HOT SPOTS” IN PERIPHERAL TISSUES
Niches for plasma cells have been described exten-
sively in the bone marrow but there is also evidence
for survival in other tissues, in particular in secondary
lymphoid tissues.22 It was also reported, that long-
lived plasma cells can be maintained in inflamed tis-
sues for long time periods, suggesting that such tis-
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sues provides niches for these cells as well.23 Periph-
eral niches for plasma cells provide an elegant way to
bring antibody-secreting plasma cells close to the an-
tigens they are specific for, and to provide high local
concentrations of antibodies there. It is also a sophis-
ticated way to contract the numbers of plasma cells
after the acute immune reaction, when the inflamed
tissue is regenerated and the plasma cells are no
longer migratory and cannot move to other niches
anymore (in: 19) They are prone to die, since the sig-
nals required for survival are no longer provided.
THE INFLAMED LUNG AS TEMPORARY SUR-
VIVAL NICHE: LYMPHOCYTES MIGRATE INTO
THE LUNG DURING AEROSOL INHALATION
BUT DO NOT PERSIST THERE
It has been reported that after allergen uptake via the
mucosa, airway-dendritic cells migrate to the draining
lymph nodes of the lung, up-regulate the expression
of costimulatory ligands, and interact with naïve T
lymphocytes, inducing an immune response (in: 24).
Airway inflammation induced by repeated allergen-in-
aerosol exposure leads to the immigration of leuko-
cytes into the lung.3,25 Plasmablasts have been re-
ported to be able to migrate from secondary lym-
phoid tissue into inflamed tissue and survive there,19
but they also could be generated within inflamed tis-
sue from precursors in ectopic immune reactions.26
We could show that already after the second allergen-
aerosol inhalation, not only B cells, T cells, kappa
lambda-positive B and antibody-secreting cells but
also IgE- and IgG1-positive B and plasma cells are de-
tectable in the lungs, suggesting that these cells had
immigrated rather than developed there.3 Their per-
sistence in the lung provided high local titers of
allergen-specific antibody. We could show, however,
that persistence of these plasma cells is dependent on
continued allergen-aerosol stimulation of the lung; af-
ter termination of aerosol treatment these plasma
cells disappear, while they are still detectable in
spleen and bone marrow where they continue to se-
crete allergen-specific antibodies.
THE DEPENDENCE OF PLASMA CELLS ON
BAFF AND APRIL SIGNALS
Members of the TNF family of ligands, specifically
BAFF (B cell activating factor of the TNF family) and
APRIL (a proliferation-inducing ligand), have been
implicated in B cell subset survival but their precise
roles in supporting post-germinal center B cell differ-
entiation and survival are still unresolved.27 Both of
these ligands bind to the receptors TACI (transmem-
brane activator and calcium modulator ligand interac-
tor) and BCMA (B cell maturation Ag), with BAFF
additionally and exclusively binding the BAFF recep-
tor (BAFF-R) while APRIL can also bind to heparin
sulphate proteoglycans. Randolph Noelle and co-
workers have investigated whether BAFF, APRIL or
both support plasma cell survival. In their recent
study they show, that either BAFF or APRIL is suffi-
cient to support plasma cell survival, but bone mar-
row plasma cells cannot survive in the absence of
both of these ligands. Their data provide important
new insights into the role of BAFF and APRIL on
long-lived humoral immunity.28 BAFF and APRIL are
probably not the only signals for plasma cell sur-
vival.23
ORGANIZATION AND MAINTENANCE OF IMMU-
NOLOGICAL MEMORY IN ALLERGY: LONG-
LIVED IgE PLASMA CELLS―KEY PLAYERS IN
CHRONIC IMMUNOPATHOLOGY
Plasma cells play a central role in infection and vacci-
nation, because they are responsible for the secretion
of protective antibodies. Most plasma cells generated
in a given immune reaction die within the first week.
This is reflected by the rapid decrease of antibody tit-
ers. In secondary systemic immune responses, anti-
body titers rise and then decrease till they reach a
low but stably maintained plateau, often about 10-20%
of the peak response. These antibody-titers are main-
tained for years after immunization (in: 29).
As the product of systemic T-cell-dependent activa-
tion of B cells, long-lived plasma cells can be an es-
sential component of immunopathology. This is par-
ticularly evident for IgE-mediated allergy, since the
half-life of IgE in serum is only about 12 hours.30 Per-
sistent production of specific IgE in the apparent ab-
sence of the corresponding antigen remains a hall-
mark of type 1 allergies in humans.31 To some extent,
allergen-specific IgE production can be transferred
by bone marrow transplantation from allergic donors
to non-allergic recipients32 although it has not been
shown unambiguously that this transfer is due to
long-lived plasma cells.
Allergies are also prolonged over extended periods
of time because secreted IgE arms basophils and
mast cells through binding via the FcεR. Immediately
after crosslinkage of FcεR-bound IgE with allergen,
basophils and mastcells secrete IL-4, thereby multi-
plying the allergic reaction.
More to the point is the demonstration of Holt and
collaborators, that IgE- (and IgG-) secreting cells in
allergic rats survive X-irradiation, which is sufficient
to eliminate memory B cells but not long-lived plasma
cells―an early demonstration of long-lived plasma
cells secreting pathogenic IgE antibodies.33
However, long-lived plasma cells may not be the
only source of allergen-specific IgE. Mucosal immune
responses may play an important role in IgE-
responses to antigenic challenges in the lung and gut,
and so far we do not know whether the mucosa-
associated lymphoid tissue generates long-lived
plasma cells. Local production of allergen-specific IgE
in inflamed tissue and the presence of allergen-
specific B cells has been described by several groups,
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plasma cell secreted IgE mast cellB cell memory B cell 
therapeutic
strategies
• SIT
• α-mIgE
• α-CD20
• proteasome inhibition
• BAFF/APRIL blockade
• stem cell transplantation
• α-IgE • anti-histamines
• corticosteroides
Fig. 1 Curent intervention strategies to treat IgE-mediated alergic disease.
but the lifespan and persistence of these cells was un-
clear, as is their origin, which could be from a local
immune reaction or an immune reaction in adjacent
lymphoid organs.34-36 Indicative of a substantial con-
tribution of long-lived plasma cells to IgE-mediated al-
lergy is the resistance of such diseases to immuno-
suppression, and the persistence of allergen-specific
IgE titres despite such therapy,37,38 since it is known
that long-lived plasma cells are resistant to immuno-
suppression.39-41
INDUCTION OF LONG-LIVED, ALLERGEN-
SPECIFIC PLASMA CELLS BY MUCOSAL AL-
LERGEN CHALLENGE
Recently, we have analyzed whether inhalation of al-
lergen can lead to the formation of long-lived,
allergen-specific plasma cells.3 We followed the gen-
eration and persistance of allergen-specific plasma
cells after ovalbumin-aerosol inhalation in a murine
model of type-I-hypersensitivity, the ovalbumin
asthma model.25 We showed that ovalbumin-specific
antibody-secreting cells, generated during systemic
sensitization, homed to and survived preferentially in
the bone marrow, but also in the spleen. Inhalation of
ovalbumin-containing aerosol in already sensitized
animals induced a profound boost of IgE, but also
IgG1 and IgA secretion. The mucosal allergen chal-
lenge induced ovalbumin-specific PC in the lung,
cells which vanished rapidly after termination of aero-
sol treatment. However, numbers of ovalbumin-
specific IgE, IgG 1 and IgA secreting,
cyclophosphamide-resistant cells in the bone marrow
increased upon aerosol treatment, indicating that
aerosol-delivery of allergen induces long-lived spe-
cific plasma cells. We have provided evidence show-
ing, that inhalation of aerosolized allergen generates
long-lived, allergen-specific IgG1-, IgA- and IgE-
secreting plasma cells which survive cytostatic treat-
ment in spleen and bone marrow.
A NEW VIEW ON THE ORGANIZATION OF
ALLERGEN-SPECIFIC IMMUNOLOGICAL MEM-
ORY
In light of our data we believe that pathogenic plasma
cells are generated in the early lifetime of an individ-
ual. This has been shown in various animal models
for human disease for e.g. lupus prone NZBW mice,
where pathogenic plasma cells were detected before
the clinical onset of disease. After disease onset, only
a few of these plasma cells generated de novo become
long-lived (in: 29).
THERAPEUTIC IMPLICATIONS TARGETING
ALLERGY
Novel approaches to treat IgE-mediated diseases are
required since present intervention concepts can not
cure allergy42 (see Fig. 1). These strategies should be
safe, provide long lasting protection and avoid the
risk of anaphylactic reactions.
A. SPECIFIC INTERVENTIONS
Allergen-specific Immunotherapy: Reprogram-
ming the Immune System for Induction of Toler-
ance to Allergen?
The only current treatment of allergic disease, be-
sides the use of symptom-based interventions such as
anti-histamines and corticosteroids to treat the in-
flammation, is specific immunotherapy (SIT). How-
ever, this treatment is transient, time consuming, ex-
pensive and may even result in life threatening reac-
tions. Immunotherapy is now performed for more
than 100 years, but still bears the risk of severe ad-
verse reactions. More importantly, many patients ex-
perience only an insufficient or just a short term re-
mission. Still, hymenoptera venom allergy can be
treated successfully in approximately 90%. Recently,
sublingual application of the allergen (SLIT) has
gained interest and compliance among the patients.
SLIT explores a novel route of administering an aller-
gen, to induce mucosal tolerance to inhaled aller-
gens. Studies of SLIT in allergic rhinitis demonstrate
Allergy for a Lifetime?
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that it reduces symptoms and use of medication and
is associated with a low incidence of systemic allergic
reactions.43,44
To date, no long term causal treatment for allergic
diseases is available and the development of new,
safe and convenient treatment protocols are urgently
needed. As the allergic immune response is charac-
terized by a dangerous deviated cellular response
such new therapies need to target the involved cell
types and their cellular products specifically.
Anti-IgE Antibody Therapy: Omalizumab
A more specific therapeutic approach for asthma is
based on decreasing the levels of circulating and cell-
bound of IgE: The one drug that has so far entered
clinical practice is a humanised monoclonal antibody
to the Fc portion of the IgE molecule, omalizumab. It
is highly effective in reducing IgE blood levels and its
established mode of delivery is by subcutaneous in-
jection. Published data claim its efficacy in clinical
practice.45 The target group of omalizumab treatment
are severe asthmatics who are still symptomatic after
being administered with high-dose inhaled corti-
costeroids plus long-acting β-agonists. However, such
therapy is limited by high costs and the requirement
of permanent or repeated application.
Combination of Omalizumab and Specific Immu-
notherapy Is Superior to Immunotherapy Alone
SIT and IgE depletion in theory could complement
each other. To determine whether combined therapy
provides better efficacy than either treatment alone,
the efficacy and safety of subcutaneously adminis-
tered anti-IgE in children and adolescents with sea-
sonal allergic rhinitis (grass- and birch pollen) was in-
vestigated.46 The authors could show, that anti-IgE
therapy achieved a protective effect independent of
the type of allergen. Additional clinical benefit of anti-
IgE antibodies was demonstrated in pollen seasons,
with or without SIT. This combination might prove
useful for the treatment of allergic rhinitis, particu-
larly for polysensitized patients.46,47 Still, the treat-
ment of allergic asthma by SIT is hampered by poten-
tial side-effects. Kopp and coworkers reported the ef-
fect of omalizumab in combination with SIT in pa-
tients with seasonal allergic rhinoconjunctivitis and
co-morbid seasonal allergic asthma incompletely con-
trolled by conventional pharmacotherapy.48 To this
end, the efficacy and safety of omalizumab in combi-
nation with SIT during the grass pollen season was
assessed. Omalizumab or placebo was started 2
weeks before SIT. The entire treatment lasted 18
weeks. Primary endpoint was daily ‘symptom load’,
the sum of daily scores for symptom severity and res-
cue medication use. Combination therapy reduced
the symptom load by 39% over SIT monotherapy.
This difference was mainly due to reduced symptom
severity, while rescue medication use did not change
significantly. Combination therapy also improved
asthma control and quality of life in the case of
asthma and rhinoconjunctivitis. The authors have
concluded, that the combination of omalizumab with
SIT was safe and reduced the symptom load signifi-
cantly.
These data show that the combination of anti-IgE
plus SIT may be beneficial for the treatment of aller-
gic diseases, offering improved efficacy, limited ad-
verse effects, and potential immune-modifying ef-
fects. Still, the cause of disease, the memory IgE B
cell, and the memory IgE-secreting plasma cell are
not addressed.
Regulation of the IgE Response at the Molecular
Level: Cellular Anti-IgE Therapy Concepts Tar-
geting IgE Memory B Cells
The classical allergic immune reaction starts seconds
or minutes after antigen contact and is committed by
IgE antibodies produced by differentiated B cells.
Treatment of IgE-mediated diseases with humanized
anti-IgE antibodies leads primarily to a decrease of
serum IgE. (in: 49,50). As a consequence, the number
of high-affinity IgE receptors on mast cells and baso-
phils decreases, leading to a lower excitability of the
effector cells. IgE bount to the high-affinity receptor
remains unaltered. The underlying biological mecha-
nism remains speculative, an effect of the therapeutic
anti-IgE antibodies on membrane IgE (mIgE) ex-
pressing B cells can not be excluded. Feichtner and
co-workers investigated this assumption by produc-
ing mouse antibodies exclusively directed against the
extracellular membrane-proximal domain of mIgE
aiming at a specific depletion of mIgE-positive B cells.
By this approach, circulating IgE memory B cells
would be eliminated from the system hindering these
cells from differentiation into IgE-secreting plasmab-
lasts and plasma cells. The interaction between the
monoclonal anti-IgE-mIgE antibody and mIgE on B
cells induced receptor-mediated apoptosis in vitro.
Signals generated by the antigen receptor are needed
not only for the maturation process but also for the
expansion of antigen-specific B cells. Antigen binding
by the antigen receptor is considered the first signal
in B cell activation. Without a second signal, consist-
ing of physical contact with the specific Th cell and
the interleukins it produces, the activation is abortive.
Such activated B cells disappear, either by an apop-
totic mechanism or after a short anergic state, in
which the B cell cannot be further activated. In pas-
sive immunization experiments they could show a
block of newly synthesized specific IgE during aller-
gen encounter. The authors conclude, that the de-
crease of allergen-specific serum IgE might be re-
lated to tolerance-inducing mechanisms stopping
mIgE-displaying B cells in their proliferation and dif-
ferentiation into plasma cells (in: 50).
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B. ALLERGEN- AND IgE- INDEPENDENT INTER-
VENTION STRATEGIES
Hinderance of the Reproduction of Plasma Cells
by Antiproliferative Immunosuppressive Ther-
apy
Memory plasma cells secreting allergen-specific IgE
antibodies are the cells of humoral memory.51 They
represent an unmet therapeutic challenge, because
they are resistant to conventional treatment, in par-
ticular to immunosuppression and anti-inflammatory
drugs. Once in their survival niches, antibody-
secreting plasma cells are resistant to environmental
threats and to immunosuppressive treatment. As
Hoyer and coworkers could show in the murine
model of systemic lupus erythematosus, treating the
mice with cyclophosphamide did not reduce long-
lived autoreactive plasma cell numbers. The plasma
cells were extremely resistant even to high-dose
treatment and continued antibody secretion.3,29
Cure of Allergy by Destruction of Memory for the
Allergen
Rituximab―Anti-CD20 Treatment
CD20 is a cell surface protein expressed on B cells
from the pre-pro B cell stage through memory cells,
but not on either pro-B cells or plasma cells. It is the
target of the monoclonal antibody Rituximab. CD20-
targeted B cell depletion therapy in humans has been
met with success in the treatment of autoimmune and
malignant B cell disorders. However, this treatment
eliminates CD27+ B cells for up to 6 months. These
cells express CD20. Bone marrow plasma cells do ex-
press little or no CD20. Accordingly, Rituximab only
induces a minor decrease in serum immunoglobulin
levels of the patients. Autoreactive and protective an-
tibodies are reduced to different degrees, indicating
that some of the cells secreting pathologic antibodies
are generated before the clinical onset of disease,
whereas others are secreted by newly generated, and
probably short-lived plasma cells,29 (in: 51).
BAFFAPRIL Blockade Using TACI-Ig
Because simultaneous BAFF and APRIL blockade de-
pletes bone marrow plasma cells in mice, this might
be an option to treat patients with malignant or auto-
immune diseases. It has recently been reported that
BAFF and APRIL blockade ablates multiple myeloma
cells in vivo more effectively than BAFF blockade
alone (in: 28). BAFF blockade does not deplete mem-
ory B cells. Thus, even upon BAFF or BAFF and
APRIL blockade, a patient’s memory B cell compart-
ment should persist and provide reactive immu-
nological memory.
The Biology of the Plasma Cell Determines its
Fate: Proteasom-blockade?
Recently, Voll and coworkers showed that the sensi-
tivity of myeloma cells toward proteasome inhibitors
directly correlates with their immunoglobulin synthe-
sis rates.52 They hypothesized that normal plasma
cells are also sensitive to proteasome inhibition. They
could show that the proteasome inhibitor bortezomib,
which is approved for the treatment of multiple
myeloma, a plasma cell neoplasia, eliminates both
short- and long-lived plasma cells by activation of the
terminal unfolded protein response. Apart from
plasma cells, rapidly proliferating lymphocytes such
as thymocytes and germinal center B cells were de-
pleted by proteasome inhibition. Resting B and T
cells, monocytes, dendritic cells and antigen presen-
tation by dendritic cells were not affected or only
moderately affected, particularly after prolonged
treatment, indicating selectivity for plasma cells.
Treatment with bortezomib depleted plasma cells
producing antibodies to double-stranded DNA, elimi-
nated autoantibody production, ameliorated glomeru-
lonephritis and prolonged survival of two mouse
strains with lupus-like disease, NZBW F1 and MRL
lpr mice.
Whether proteasome blockade would also success-
fully stop allergic symptoms by depletion of long-lived
IgE plasma cells, secreting pathogenic IgE, needs to
be investigated in the near future.
Depletion of Autoreactive Immunologic Memory
Followed by Autologous Hematopoietic Stem
Cell Transplantation
Immunoablative chemotherapy followed by autolo-
gous hematopoietic stem cell transplantation (ASCT)
has emerged as a promising experimental therapy for
severely affected patients, achieving treatment-free,
long-term remission in about 50% of patients refrac-
tory to conventional treatments.53 Alexander and co-
workers report the long-term reconstitution of T- and
B cell subsets and serologic changes in 7 patients
with SLE for up to 8 years after receiving immunoab-
lation and ASCT.53 They show that immunoablation
with high-dose chemotherapy, methylprednisolone,
and anti-thymocyte globulin efficiently depletes naive
and memory T and B cells and long-lived plasma
cells, including those that are autoreactive. In addi-
tion, immunoablation plus ASCT reactivated the thy-
mus, leading to the development of a tolerant, “juve-
nile” adaptive immune system, which is reflected by
long-term, treatment-free, clinical remissions, essen-
tially a reset of the immunesystem with efficient de-
pletion of autoreactive plasma cells.
Addressing the T Cell Compartment to Combat
Allergic Diseases
Various populations of regulatory T (Treg) cells have
been shown to play a role in the maintenance of pe-
ripheral homeostasis and the establishment of protec-
tive immune responses. Both, naturally occurring
CD4+CD25+ Treg cells and inducible populations of
allergen-specific, IL-10-secreting Treg type 1 cells in-
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hibit allergen-specific effector cells in experimental
models. Skewing of allergen-specific effector T cells
to a protective, regulatory phenotype appears to be a
key event in the development of a healthy immune re-
sponse to allergens and a successful outcome in
allergen-specific immunotherapy (in: 54).
Still, it is debated, whether allergen-specific im-
mune reactions can develop because regulatory B
and T cells do not function correctly, or whether
allergen-specific cells withdraw themselves from ef-
fective control by regulatory cells. Further it is possi-
ble, that the physiologic control for the allergen is
leaky.
We could show, that the transcriptional repressor
twist1, as an antagonist of nuclear factor kappa B-
dependent cytokine expression, is involved in the
regulation of inflammation-induced immunopathol-
ogy. Ectopic twist1 expression reduced the frequen-
cies of cytokine-expressing reactivated Th1 or Th2,
or of Th cells that had been stimulated without addi-
tion of polarizing cytokines, to 40-50% of the con-
trols.55
CONCLUSION
Summarizing clinical therapeutic interventions and
experimental data obtained so far we have to realize,
that cure of allergy is more complex than probably as-
sumed.
Still, the most promizing approaches are aiming at
the pathogenic, symptom-causing IgE antibodies al-
though this is not curative at all.
Therefore, addressing the IgE-secreting allergen-
specific plasma cell, or the IgE memory B cell is the
only curative concept, which has to find its way into
the clinics in the coming future.
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